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 The aim of this study was to test the effects of vitamin 
E on fetal lung growth in rats with congenital diaphrag-
matic hernia (CDH). Experimental congenital diaphragmatic 
hernia (CDH) was induced in rat fetuses by maternal ad-
ministration of 100 mg nitrofen by gastric gavage on day 
9.5 of gestation. Vitamin E was provided at days 16-20 of 
gestation, at 30 IU/day. Cesarean section was performed at 
day 21 of gestation. Immunohistochemistry was performed 
using anti-surfactant protein A (SP-A) and anti-SP-B polyclonal 
antibodies. RT-PCR evaluated SP-A and SP-B mRNA expres-
sions. The lung weight/body weight ratio in rats with CDH 
was lower than the control (p<0.01). The number of type II 
pneumocytes positive for SP-A in untreated CDH rats (n=20) 
was lower than the control (n=20). The relative amounts of 
SP-A and SP-B were significantly higher in vitamin E-
treated CDH rats (n=20) than untreated CDH rats (p<0.05). 
Our results suggest that antenatal vitamin E treatment in-
creases the production of surfactant proteins in hypoplastic 
lung of rats with the CDH. 
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Introduction
 Recent reports on congenital diaphragmatic hernia 
(CDH) show a variable mortality rate ranging from 8 
to 79%". The most common cause of death in severely 
affected infants is pulmonary hypoplasia. Studies in 
animal models and clinical reports have indicated that 
lung compliance, pressure-volume curve, and hyaline
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membrane formation of newborns with CDH resemble 
those seen in premature newborns with surfactant 
deficiency 2'3'. Recent studies have reported low levels 
of the surfactant protein A (SP-A) in human CDH case 
s" as well as in rats with experimentally-induced CD 
H 5'. SP-A levels are also reduced in the amniotic fluid 
of pregnancies complicated by CDH, showing a close 
correlation between SP-A amniotic concentration and 
prognosis 6'. 
 Our research strategy has been to identify possible 
therapeutic interventions in utero that may improve 
lung growth and maturity. Previous reports have shown 
that prenatal glucocorticoids improve pulmonary ma-
turity in fetal rat and sheep models of CDH based on 
biochemical, histological, and physiological changes 7 9'. 
However, prenatal glucocorticoid therapy does not seem 
to alter fetal lung growth"'. Recent studies have shown 
that vitamin E accelerates the in vitro growth and com-
plexity of the hypoplastic rat fetal lung and that prena-
tal vitamin E treatment in vivo improves pulmonary 
hypoplasia in fetal rats with CDH"'. The observation 
that vitamin E can enhance fetal lung growth sug-
gests a role for oxidative processes in altered lung de-
velopment and a possible therapeutic strategy for the 
treatment of lung hypoplasia associated with CDH. 
 The aim of the present study was to investigate 
whether maternal administration of vitamin E has any 
ffect on the expression of SP-A and SP-B by 
immunohistochemistry and reverse transcription-




 Adult Sprague-Dawley rats were bred after over-
night controlled mating. Observation of a positive 
smear was considered a proof of pregnancy; the day 
of observation was determined as day 0. At 9.5 days
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of pregnancy (term, 22 days) 100 mg of nitrofen 
(Wako Chemical, Osaka, Japan) dissolved in olive oil 
was administered as a single dose by gastric gavage 
under a brief anesthesia. Control rats were treated 
with the same dose of olive oil but without nitrofen. 
This was followed by maternal administration of 30 
IU of vitamin E at 16-20 days of gestation to a group 
of nitrofen-treated rats. 
 The dose of 150 IU was chosen according to Islam 
et al."'. 
 Cesarean section was performed on day 21 of gesta-
tion. Only fetuses with left-side CDH were entered in 
this study. The fetuses were divided into 3 groups, each 
consisting of 20 rats: the first group represented the 
control, the second represented rats with nitrofen-
induced left side CDH, and the third group represented 
newborns with nitrofen-induced left side CDH treated 
with vitamin E. Left lungs were removed from the 
chest, and half of the sample from each group (n=10) 
was processed for RNA extraction, while the other half 
was processed for histological examination. Left lung 
growth and development was assessed quantitatively 
according to the method of Saitoh and Saitoh12' using 
three histopathological parameters. These included the 
size of lung acini, number of generations of the termi-
nal airspaces and the mean alveolar diameter. The three 
parameters were measured in 30 sections in each case"'.
Immunohistochemistry
 The left lung tissue was fixed with 4% formaldehyde 
for 24 hours at 4°C. The samples were embedded in 
paraffin and stored at -80°C. Frozen tissue blocks were 
cut into 5-,um thick sections and mounted on polylysine-
coated glass slides. 
 Immunohistochemistry was performed using the la-
beled streptavidin biotin (LSAB) method (Dako, Japan). 
A rabbit antihuman SP-A polyclonal antibody (Chemicon, 
Temecula, CA) at 1:100 dilution and a rabbit anti-rat 
polyclonal SP-B antibody (Chemicon) at 1:200 dilution, 
were used as primary antibodies. Biotin-labeled goat 
anti-rabbit (Dako) was used as secondary antibody. All 
sections were incubated with a solution of horseradish 
peroxidase-conjugated streptavidin (Dako). Peroxidase 
activity was determined using 3,3'-diaminobenzidine 
tetrahydrochloride (Dojindo Chemicals Co., Osaka, Japan) 
in PBS, containing 0.01% H202 . The sections were 
counterstained with hematoxylin. For semiquantitative 
analysis, immunohistochemically-stained sections were 
scored into one of four grades (-, ±, +, ++) based on 
the frequency and intensity of positively-stained 
epithelial cells. The above analysis was conducted by 
three investigators and the final score of each area
analyzed was determined by consensus.
Reverse transcription polymerase chain reaction"'
  Total RNA was extracted from each left lung tissue 
using RNAgents reagent (Promega, Madison, WI), ac-
cording to the protocol recommended by the manufac 
ture. Total RNA was redissolved in diethyl pyrocarbonate 
(DEPC)-treated water and mRNA was isolated using 
streptavidin magnet particles and biotin labeled oligo 
(dT) probe (Promega). Polymerase chain reaction (PCR) 
was used as described recently"). The specific primer 
sets used to amplify SP-A, SP-B, and 8-actin cDNA 
and estimated size of PCR products are listed in Table 
1. PCRs for SP-A (at 94°C for 30 seconds, at 56°C for 
30 seconds, at 72°C for 60 seconds; 22cycles), SP-B (at 
94°C for 30 seconds, at 60°C for 0 seconds, at 72°C for 
60 seconds, and at 72°C for 60 seconds; 26 cycles), and 
,8-actin (at 94°C for 40 seconds, at 68°C for 40 seconds, 
and at 72°C for 90 seconds; 27 cycles) were performed 
on each sample. The PCR conditions used were con-
firmed in a series of preliminarily studies to be within 
the exponential phase. The PCR products were 
electrophoresed on 2.0% agarose gel and stained by 
ethidium bromide to visualize DNA bands. The image 
of each band was quantitated by an image analysis 
software (IP Lab Gel, Signal Analytic Co.). The relative 
amount of mRNA, and SP-A and SP-B levels in each 
case were expressed as a ratio of the band intensity 
divided by that of 8-actin.
Table 1. RT-PCR primer sequences for SP-A, SP-B and 13-
actin.
                                                             Product size 
        Primer Sequence 5-Y (bp) 
SP-A Sense GGA AGC CCT GGG ATC CCT GGA 557 
     Antisense TGG GTA CCA GTT GGT GTA GT 
SP-B Sense GAG GAT ATT GTC CAC GTG CT 725 
     Antisense ATA GCC TGT TCA CTG GTG T 
(3-actin Sense CGT CAT ACT CCT GCT TGC TGA AAT GGC TGC G 838 
     Antisense CGT CAT ACT CCT GCT TGC TGA TCC ACA TCT GC
Statistical analysis
 All data were expressed as mean ± SD. Differences 
between groups were examined for statistical signifi-
cance using the Student's t- test. A P value less than 
0.05 denoted the presence of a statistically significant 
difference. All statistical analyses were performed using
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StatView software (Abacus Concepts, Barkley, CA).
Results
 Table 2 shows the fetal wet lung/body weight ra-
tios of the three groups. The ratios of rats with CDH 
treated or untreated with vitamin E were significantly 
lower than that of the control group (p<0.01, each). 
Histopathological evaluation of the lungs showed sig-
nificant reductions of all three parameters (size of lung 
acini, number of generations of the terminal airspaces 
and the mean diameter of alveoli) in rats with CDH 
compared with the control group (Table 2). However, 
administration of vitamin E significantly improved 
histological parameters compared with the untreated 
group.
Table 2. Effects of vitamin E on fetal lung/body weight and 
lung growth in rats with nitrofen-induced congenital dia-
phragmatic hernia (CDH).
                                                    Untreated rats VitaminE-treated 
                                 Control rats with CDH CDH rats
                               (n=10) (n=10) (n=10) 
Lung/Body weight ratio (%) 2 35±0 23 1 53±0 25* 1 69±0 38* 
Histopathological parameters 
size of lung acinus (ysm) 331±61 197--34* 233±36*t 
number of generations of terminal airspace 333+-048 2 58±0 50* 2 66±0 48*' 
mean diameterof alveolus (ysm) 40 6±5 1 24 6±4 5* 36 6±7 8* t
*p<001
, compared with the control, tp<0 05, compared with untreated CDH group
SP-A and SP-B Immunohistochemistry
 Many SP-A positive type II alveolar epithelial cells 
were noted in the lungs of control newborn rats (Fig. 
IA), whereas only few cells were SP-A immunoreactive 
in rats with CDH (Fig. 1B). Vitamin E-treated CDH 
rats showed a significantly higher number of SP-A 
positive type II pneumocytes compared with untreated 
newborn rats (Fig. 1C). SP-B was not expressed in con-
trol rats (group 1, Fig. 2A) compared with few 
immunoreactive cells in lungs of rats with CDH 
(group 2). The number of SP-B-positive type 2 cells 
was significantly higher in vitamin E-treated newborn 
rats with CDH than in the untreated group (group 3, 
Fig. 2C).
Fig 1. SP-A immunohistochemistry. (A) Control group: many 
type II pneumocytes are positive for SP-A. (B) Rats with 
CDH: note the presence of few immunopositive type II cells. 
(C) Vitamin E-treated rats with CDH: note the high expres-
sion of SP-A relative to A and B (original magnification x 
100).
Reverse transcription polymerase chain reaction
 The PCR conditions described above successfully 
yielded amplified fragments of expected sizes for SP-
A, SP-B and b-actin. The intensity of the band corre-
sponding to b-actin mRNA was similar among the 
groups (Fig. 1). The intensity of SP-A bands was 
slightly stronger in the control than untreated CDH 
rats, suggesting reduced levels of SP-A in CDH lung.
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Table 3. Expression of SP-A and SP-B in control rats and 
rats with nitrofen-induced congenital diaphragmatic hernia 
(CDH).
                                                         VitarninE-
                                               Untreated rats 
                                  Control rats treated CDH 
                                         with CDH 
                                                                  rats
Immunoreactivityto SP-A§ + ± ++ 
Immunoreactivityto SP-B§ + + ++ 
Relativeamountof SP-A mRNA (±SD) 1.34±0.06 1.23±0.20 1.43±0.24' 
Relative amount of SP-B mRNA (±SD) 1.19±0.10 1.33±0.25* 1.53±0.21*'
§Positive cells in alveoli: ++ many; + some; ± few; - almost none. 
* p<0.01, compared with the control, 'p<0.05, compared with untreatedCDH group,
Discussion
Fig 2. SP-B immunohistochemistry. (A) Control group: many 
type II pneumocytes are positive for SP- B. (B) Rats with 
CDH: note the presence of few immunopositive type II cells. 
(C) Vitamin E-treated rats with CDH: note the high expres-
sion of SP-B relative to A and B (original magnification x 
100).
The intensities of SP-B and SP-A bands were stronger 
in vitamin E-treated newborn rats with CDH com-
pared to untreated CDH rats (Table 3). Furthermore, 
the relative amount of SP-A mRNA was slightly re-
duced in the CDH group compared with the controls. 
In vitamin E-treated group, the relative amounts of 
SP-A and SP-B mRNAs were significantly higher than 
in untreated CDH rats (P<0.05, Table 3).
 Pulmonary surfactant, a complex mixture of lipid 
and proteins, provides phospholipid for the formation 
of the surface active film that lines air spaces and pre-
vents alveolar collapse. The fetal lung acquires the ca-
pacity for surfactant synthesis relatively late in gesta-
tion. Augmented surfactant synthesis and secretion 
are initiated after completion of 85 to 90% of gestation 
in all mammalian species thus far studied15 '6'. In the 
human fetus, type II cells are first identified in the 
terminal sacs at 20 to 22 weeks of gestation, however, 
secretion of surfactant into the amniotic fluid is de-
tectable only after 30 to 32 weeks of gestation15'. In 
the rat, levels of SP-A mRNA and protein, which are 
first detected on day 18 of gestation, increase mark-
edly through day 21 to approximately 50% of the 
adult levels"'. SP-B is first detected in fetal lung tissue 
on day 18 of gestation and attains adult level by day 
20 of gestation"). 
 Vitamin E is the genetic term used for a group of at 
least eight compounds exhibiting biological activity of 
a-tocopherol, which has the highest antioxidant activity"). 
Vitamin E is a potent intracellular chain-breaking an-
tioxidant and is associated with glutathione, selenium, 
and vitamin C for regeneration of the tocopheryl 
radical"'. Current evidence strongly points to the role 
for vitamin E in prevention of cardiovascular disease"'. 
Previous observations that vitamin E can enhance fetal 
lung growth may suggest the involvement of oxida-
tive processes in altered lung development and a pos-
sible therapeutic strategy for the treatment of lung 
hypoplasia associated with CDH. Studies in neonatal 
models have shown that increased oxygen concentra-
tions lead to dysplastic and altered lung cell growth 
patterns as well as changes in insulin-like growth
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factor gene expression, which may be caused by oxy-
gen-derived free radicals, suggesting that antioxidants 
may prevent growth alterations"'. The mechanisms 
through which fetal lung growth is induced by vita-
min E remain unclear and are currently under study 
in our laboratory. 
  In conclusion, we analyzed the expression of SP-A 
and SP-B at both transcriptional and translational 
level after prenatal vitamin E treatment. Vitamin E in-
creases the rate of transcription of surfactant proteins 
acting directly on type II cells. It exhibits a dose-
dependent biphasic effect on the levels of SP-A, acting 
on SP-A mRNA; at low concentration, vitamin E in-
creases SP-A gene transcription whereas at high con-
centration the upregulation of transcription is modu-
lated by a reduction on mRNA stability resulting in a 
reduction of SP-A synthesis. The combined use of 
semiquantitative RT-PCR and immunohistochemistry 
in the present study provided the opportunity to evalu-
ate the increased transcription and translation of in 
vivo antenatal vitamin E treatment at a dosage that 
does not interfaces with somatic growth. In our study, 
there was a trend, but not statistically significant, in 
spite of the treatments of vitamin E. This could be due 
to three reasons. Firstly, our numbers were probably 
too small to demonstrate a significant difference. 
Secondly, we used smaller doses of vitamins for short 
duration. It remains to be seen if maternal supplemen-
tation of large doses of antioxidants would reduce the 
oxidative stress in infants. Thrid reason could be both 
low maternal placental transfer and fetal lipid trans-
port peculiarities. An attractive scheme would be to 
combine the early growth effects of antioxidants with 
later maturation and differentiation effects on surfac 
tant production and alveolar formation by glucocorticoids. 
We are currently studying the effects of this combina-
tion therapy in rats with experimentally-induced CDH.
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